With a wealth of experience in preclinical spinal muscular atrophy (SMA) studies, PsychoGenics is an ideal choice to partner with on your preclinical studies.
SMA is a rare yet devastating autosomal recessive motor neurodegenerative disease, presenting as the leading genetic cause of death among infants and toddlers. At PsychoGenics, we are committed to broadening our understanding of SMA and developing innovative approaches for therapeutic interventions.
Delta 7 Model: A Rapidly Progressing SMA Model
The Δ7SMN+/+;SMN2+/+;Smn-/- neonatal mouse model also referred at Delta 7 is widely used for screening potential therapies. Delta 7 mice have a life span of 17 days with a median survival of 12 days. Rapidly after birth, Delta 7 animals display loss of body weight and motor strength. Due to this rapid symptom progression, PsychoGenics developed motor dysfunction behavioral tests and drug delivery methods to enable treatment as early as birth, including ICV drug administration. In addition, genotyping is performed in less than 24 hours.
Paving the Way for Your Preclinical SMA Research Breakthrough
PsychoGenics is a leader in SMA research innovations, aiding your pursuit of significant breakthroughs. Collaborate with us to address the challenges of SMA, paving a brighter future for young patients and their families.
Explore our areas of neurodegenerative disease specialization: